Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 4Brain Neoplasms 4Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 119Temozolomide 109Carboplatin 52Filgrastim 46Vincristine 42Etoposide 39Cyclophosphamide 36Chemotherapy, Adjuvant 36Cisplatin 35Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 23Lomustine 22Thiotepa 21Methotrexate 19Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Topotecan 12Paclitaxel 12Ifosfamide 12Drug Therapy 12Thalidomide 11Radiation 11sargramostim 10Erlotinib Hydrochloride 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Central Nervous System Neoplasms × TPI-287 × Clear all
NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 7 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡